Videos

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, and protect patients who otherwise disappear from care.

Jordi Mones, MD, PhD, discusses what is believed to be the first direct-to-phase 2 trial testing an optogenetic gene therapy to restore vision lost to GA.

Jonathan Gloth, MD, discusses how a dual Tie2/VEGF mechanism could reduce injection burden and the consequences of missed doses in wet AMD.

John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging therapies including a C1q inhibitor and cell-based options.

Reem Amine, MD, discusses why clinic distance predicts loss to follow-up in geographic atrophy and shares one retention check practices can implement now.

At WIO 2026, Durga Borkar, MD, discussed DAVIO2 trial results for EYP-1901 in wet AMD.

Dante Pieramici, MD, discusses EYP-1901, a sustained-delivery tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 JAK/STAT signaling, in the phase 3 COMO and CAPRI diabetic macular edema trials.

Dante Pieramici, MD, breaks down the phase 3 COMO and CAPRI trials of EYP-1901 (Duravyu), an insert designed to ease treatment burden in diabetic macular edema.

A former US Navy flight surgeon turned three-time CMO, David J. Tanzer, MD, ABO, reflects on a career built at the pharma-clinic bridge.

Host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Flaxel and Dr. Rudnick about how a home monitoring device could reshape treatment decisions and reduce office visits for patients with wet AMD.

25.5% of patients labeled with MacTel2 didn't meet diagnostic criteria, most often due to cystic OCT changes and telangiectatic vessels mistaken for the disease.

In the latest episode of The Wills Retina Report, Dr. Regillo and Dr. Hsu discuss why sustained delivery with the port delivery system may outperform even closely monitored intermittent injections.

Stuart Therapeutics presented preclinical data at OIS Retina 2026 on a non-gene-specific collagen mimetic peptide that preserved retinal thickness and visual function in 2 mouse models of inherited retinal disease.

Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.

Real-world SPECTRUM data shows strong fluid resolution and vision gains by week 12, with low adverse events and no retinal vasculitis.

Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients.

A single vorolanib intravitreal insert extended time to supplemental anti-VEGF injection vs aflibercept in previously treated DME at 24 weeks in phase 2 VERONA; pivotal phase 3 trials COMO and CAPRI are now underway.

For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the clinic with a broader view of the field.

A University of Chicago-led ASRS 2026 poster explores how large language and vision-language models could help retina specialists manage imaging, records, and clinical trial matching—without replacing physician judgment.

At ASRS 2026, the dual inflammasome inhibitor K8 slowed geographic atrophy lesion growth by up to 54% over 6 months in a phase 2 trial and showed a visual acuity advantage in eyes with extrafoveal lesions, with no drug-related serious adverse events.

Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central serous chorioretinopathy (CSCR)

Carl C. Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, with strong safety through 4 years of follow-up.

In a first-in-human Phase 1 trial, a single TH103 injection improved vision and reduced fluid in treatment-naive wet AMD, with roughly a third of patients needing no retreatment through 6 months.

5-year OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained aflibercept expression and no new safety signals, in a high-need population with nAMD.

Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.